Literature DB >> 2044507

An investigation of the incidence of chronic obstructive pulmonary disease (COPD) in random populations of Swiss horses.

V Bracher1, R von Fellenberg, C N Winder, G Gruenig, M Hermann, A Kraehenmann.   

Abstract

The incidence of Chronic Obstructive Pulmonary Disease (COPD) in Switzerland was determined in three groups of horses selected at random. Group A (97 horses) and Group B (93 horses) had no history of respiratory disease, but Group C (113 horses) had a history of lower respiratory tract disease. All horses were examined by auscultation of the respiratory tract under forced breathing, endoscopic examination of the upper and lower respiratory tract, arterial blood gas analysis at rest and cytological examination of respiratory secretions (RS). Fifty-four per cent of the horses in Group A and 54.8 per cent of Group B were diagnosed as suffering clinical COPD and only 12.4 per cent of horses in Group A and 8.6 per cent in Group B had no detectable abnormalities in their lower respiratory tracts. In Group B, 19.4 per cent were considered to be suffering from parasitic pulmonary disease indicated by elevated numbers of eosinophils in their RS. Pharyngeal lymphoid hyperplasia was exhibited in 70.1 per cent of Group A and 74.2 per cent of Group B. Cytological examination of RS was useful to determine if the secretions found in the trachea originated from the upper or lower respiratory tract. Arterial blood gas analysis revealed no significant differences between healthy horses and those with subclinical or mild COPD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044507     DOI: 10.1111/j.2042-3306.1991.tb02738.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  7 in total

1.  The variability and repeatability of indices derived from the single-breath diagram for CO2 in horses with chronic obstructive pulmonary disease and the effect of lobelin hydrochloride on these indices.

Authors:  C Herholz; R Straub; A Busato
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

2.  The Hygienic Status of Different Forage Types for Horses-A Retrospective Study on Influencing Factors and Associations with Anamnestic Reports.

Authors:  Sandra Intemann; Bernd Reckels; Dana Schubert; Petra Wolf; Josef Kamphues; Christian Visscher
Journal:  Vet Sci       Date:  2022-05-06

3.  Spi2 gene polymorphism is not associated with recurrent airway obstruction and inflammatory airway disease in thoroughbred horses.

Authors:  Aline Correa da Silva; Karin Erica Brass; Elgion da Silva Loreto; Myriam Elizabeth Vinocur; Ricardo Pozzobon; Marcos da Silva Azevedo
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

4.  Immunomodulatory asthma therapy in the equine animal model: A dose-response study and evaluation of a long-term effect.

Authors:  John Klier; Carolin Bartl; Sabine Geuder; Katharina J Geh; Sven Reese; Lutz S Goehring; Gerhard Winter; Heidrun Gehlen
Journal:  Immun Inflamm Dis       Date:  2019-05-29

Review 5.  Inhalative Nanoparticulate CpG Immunotherapy in Severe Equine Asthma: An Innovative Therapeutic Concept and Potential Animal Model for Human Asthma Treatment.

Authors:  John Klier; Sebastian Fuchs; Gerhard Winter; Heidrun Gehlen
Journal:  Animals (Basel)       Date:  2022-08-16       Impact factor: 3.231

6.  The Microbiological Quality of Concentrates for Horses-A Retrospective Study on Influencing Factors and Associations with Clinical Symptoms Reported by Owners or Referring Vets.

Authors:  Sandra Intemann; Bernd Reckels; Dana Carina Schubert; Petra Wolf; Josef Kamphues; Christian Visscher
Journal:  Vet Sci       Date:  2022-08-05

7.  Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction.

Authors:  Ann Kristin Barton; Tarek Shety; Angelika Bondzio; Ralf Einspanier; Heidrun Gehlen
Journal:  BMC Vet Res       Date:  2016-12-09       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.